NCI Grants Establish 18 Biomarkers Developmental Laboratories

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

BETHESDA, Md-Nearly $8 million in grants will help 17 organizations establish 18 Biomarkers Developmental Laboratories, part of the National Cancer Institute’s new Early Detection Research Network. The laboratories are charged with identifying, characterizing, and refining techniques for finding molecular, genetic, and biologic biomarkers.

BETHESDA, Md—Nearly $8 million in grants will help 17 organizations establish 18 Biomarkers Developmental Laboratories, part of the National Cancer Institute’s new Early Detection Research Network. The laboratories are charged with identifying, characterizing, and refining techniques for finding molecular, genetic, and biologic biomarkers.

Two laboratories will be established at the University of Maryland School of Medicine. Other grants went to the University of Colorado, Yale University, Lombardi Cancer Center, the University of South Florida, Northwestern University, Johns Hopkins University, the University of Michigan, Genetica, Inc. (Cold Spring, NY), Mount Sinai School of Medicine, Duke Medical Center, Thomas Jefferson University, the University of Pittsburgh, M.D. Anderson Cancer Center, University of Texas Southwestern Medical Center (Dallas), Eastern Virginia Medical School, and the University of Washington.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.